Market Overview

NetworkNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report

Share:

Satsuma Pharmaceuticals (NASDAQ:STSA) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, "We are BUY rated on Satsuma given the potential we see for STS101 in the acute treatment of migraines. Phase 3 data is expected in 2H 2020, with regulatory filing in late 2021 […]

Satsuma Pharmaceuticals (NASDAQ:STSA) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, "We are BUY rated on Satsuma given the potential we see for STS101 in the acute treatment of migraines. Phase 3 data is expected in 2H 2020, with regulatory filing in late 2021 and potential market entry in late 2022/early 2023. We see STS101 as a differentiated asset delivering dihydroergotaminemesylate (‘DHE') intranasally that can be used by patients who do not respond to current treatment options. We estimate probability-adjusted sales of ~$300MM in 2028 along with a 70% probability of success."

To request access to the full report, visit http://nnw.fm/SaZ9d

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate ("DHE"), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development. Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For more information, visit the company's website at www.SatsumaRX.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com